Cytokinetics CEO Blum sells 7,500 shares under plan

Blum's option holding after the transaction was 141,745 shares; each of two trusts held 2,083 shares with beneficial ownership disclaimed.

Rhea-AI Filing Summary

Cytokinetics (CYTK) President & CEO Robert I. Blum exercised 7,500 non-qualified stock options on October 12, 2026, at an exercise price of $10.60 per share, acquired 7,500 common shares, and sold 7,500 shares at $62.88 per share under a Rule 10b5-1 plan. His option holding was 141,745 shares following the exercise. The Bridget Blum 2003 Irrevocable Trust and The Brittany Blum 2003 Irrevocable Trust each held 2,083 common shares; Blum, a co-trustee of each, disclaimed beneficial ownership.

Insider Trade Summary 10b5-1

Exercise and Sale: 7,500 shares ($392K approx. pre-tax spread)

Exercise and Sale 5 txns

Insider Blum Robert I

Role President & CEO

Sold 7,500 shs ($472K)

Approx. gross sale proceeds $472K

Approx. exercise cost $80K

Approx. pre-tax spread $392K

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (Right to Buy)	7,500	$0.00	$0.00
Exercise	Common Stock	7,500	$10.60	$80K
Sale	Common Stock	7,500	$62.88	$472K
holding	Common Stock F1	--	--	--
holding	Common Stock F2	--	--	--

Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 141,745 contracts (Direct); Common Stock — 278,544 shares (Direct); Common Stock — 2,083 shares (Indirect, by Trust 1. Beneficial Ownership disclaimed.); Common Stock — 2,083 shares (Indirect, by Trust 2. Beneficial Ownership Disclaimed.)

Footnotes (2)

1. F1. Shares held by The Bridget Blum 2003 Irrevocable Trust, of which reporting person is a co-trustee. Reporting person disclaims any beneficial ownership interest in the Shares.
2. F2. Shares held by The Brittany Blum 2003 Irrevocable Trust, of which reporting person is a co-trustee. Reporting person disclaims any beneficial ownership interest in the Shares.

Key Figures

Options exercised: 7,500 shares Option exercise price: $10.60 per share Common shares acquired: 7,500 shares +5 more

8 metrics

Options exercised 7,500 shares October 12, 2026

Option exercise price $10.60 per share Options exercised on October 12, 2026

Common shares acquired 7,500 shares October 12, 2026

Common shares sold 7,500 shares October 12, 2026

Sale price $62.88 per share Common shares sold on October 12, 2026

Option holding following exercise 141,745 shares October 12, 2026

Shares held by The Bridget Blum 2003 Irrevocable Trust 2,083 shares Blum disclaimed beneficial ownership

Shares held by The Brittany Blum 2003 Irrevocable Trust 2,083 shares Blum disclaimed beneficial ownership

Key Terms

Non-Qualified Stock Option (Right to Buy), Rule 10b5-1, exercise price, beneficial ownership

4 terms

Non-Qualified Stock Option (Right to Buy) financial

"Non-Qualified Stock Option (Right to Buy)"

Rule 10b5-1 regulatory

"transactions were made under a Rule 10b5-1 plan"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

exercise price financial

"exercise price of $10.60 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

beneficial ownership financial

"disclaims any beneficial ownership interest in the Shares"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CYTK shares did Robert I. Blum sell?

Robert I. Blum sold 7,500 common shares at $62.88 per share on October 12, 2026, under a Rule 10b5-1 plan.

When did Robert I. Blum's CYTK options expire?

The reported non-qualified stock option had an expiration date of February 28, 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/13/2026 - 04:01 PM EDT Accepted by SEC EDGAR 10/13/2026 - 04:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Blum Robert I

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/12/2026		M		7,500	A	$10.6	286,044	D
Common Stock	10/12/2026		S		7,500	D	$62.88	278,544	D
Common Stock								2,083	I	by Trust 1. Beneficial Ownership disclaimed.(1)
Common Stock								2,083	I	by Trust 2. Beneficial Ownership Disclaimed.(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (Right to Buy)	$10.6	10/12/2026		M			7,500	03/28/2017	02/28/2027	Common Stock	7,500	$0	141,745	D

Explanation of Responses:

1. Shares held by The Bridget Blum 2003 Irrevocable Trust, of which reporting person is a co-trustee. Reporting person disclaims any beneficial ownership interest in the Shares.

2. Shares held by The Brittany Blum 2003 Irrevocable Trust, of which reporting person is a co-trustee. Reporting person disclaims any beneficial ownership interest in the Shares.

	/s/ John O. Faurescu, attorney-in-fact for Mr. Blum	10/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)